Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab in Interstitial Cystitis/Painful Bladder Syndrome
NCT01060254Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Apr 2010
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of fulranumab in interstitial cystitis (IC), sponsored by Johnson & Johnson. Started Apr 2010; status: terminated.
02
Drugs
fulranumab
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT01060254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01060254.